- Home
- AXR vs GNLX Comparison
AXR vs GNLX Comparison
Compare AXR & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AXR
- GNLX
- Stock Information
- Founded
- AXR 1961
- GNLX 2001
- Country
- AXR United States
- GNLX United States
- Employees
- AXR N/A
- GNLX N/A
- Industry
- AXR Homebuilding
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- AXR Real Estate
- GNLX Health Care
- Exchange
- AXR Nasdaq
- GNLX Nasdaq
- Market Cap
- AXR 117.0M
- GNLX 128.0M
- IPO Year
- AXR N/A
- GNLX 2023
- Fundamental
- Price
- AXR $21.58
- GNLX $3.35
- Analyst Decision
- AXR
- GNLX Strong Buy
- Analyst Count
- AXR 0
- GNLX 5
- Target Price
- AXR N/A
- GNLX $16.20
- AVG Volume (30 Days)
- AXR 6.2K
- GNLX 92.0K
- Earning Date
- AXR 09-12-2025
- GNLX 08-07-2025
- Dividend Yield
- AXR N/A
- GNLX N/A
- EPS Growth
- AXR 89.60
- GNLX N/A
- EPS
- AXR 2.37
- GNLX N/A
- Revenue
- AXR $49,694,000.00
- GNLX N/A
- Revenue This Year
- AXR $12.31
- GNLX N/A
- Revenue Next Year
- AXR $8.40
- GNLX N/A
- P/E Ratio
- AXR $9.06
- GNLX N/A
- Revenue Growth
- AXR N/A
- GNLX N/A
- 52 Week Low
- AXR $17.60
- GNLX $1.95
- 52 Week High
- AXR $39.68
- GNLX $5.89
- Technical
- Relative Strength Index (RSI)
- AXR 43.71
- GNLX 53.63
- Support Level
- AXR $21.45
- GNLX $3.51
- Resistance Level
- AXR $22.91
- GNLX $4.07
- Average True Range (ATR)
- AXR 0.53
- GNLX 0.22
- MACD
- AXR -0.03
- GNLX 0.00
- Stochastic Oscillator
- AXR 8.90
- GNLX 51.92
About AXR AMREP Corporation
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec), Lung, and Pancreatic Cancer.